These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16138881)

  • 1. Identifying the high risk patient with coronary artery disease--is ejection fraction all you need?
    Buxton AE
    J Cardiovasc Electrophysiol; 2005 Sep; 16 Suppl 1():S25-7. PubMed ID: 16138881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of sudden cardiac death.
    Cannom DS
    J Cardiovasc Electrophysiol; 2005 Sep; 16 Suppl 1():S21-4. PubMed ID: 16138880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.
    Buxton AE; Lee KL; Hafley GE; Pires LA; Fisher JD; Gold MR; Josephson ME; Lehmann MH; Prystowsky EN;
    J Am Coll Cardiol; 2007 Sep; 50(12):1150-7. PubMed ID: 17868806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
    Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
    Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICD therapy in coronary artery disease. A reappraisal in 2005.
    Grönefeld G; Manegold J; Israel CW; Hohnloser SH
    Herz; 2005 Mar; 30(2):82-6. PubMed ID: 15875095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy.
    Klein GJ; Krahn AD; Skanes AC; Yee R; Gula LJ
    J Cardiovasc Electrophysiol; 2005 Sep; 16 Suppl 1():S28-34. PubMed ID: 16138882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implanted defibrillators and primary prevention of sudden cardiac death: where are we today?
    Ray IB; Reddy VY
    Int J Cardiol; 2005 Jan; 98(1):15-20. PubMed ID: 15676160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular ejection fraction for sudden death risk stratification and guiding implantable cardioverter-defibrillators implantation.
    Buxton AE; Ellison KE; Lorvidhaya P; Ziv O
    J Cardiovasc Pharmacol; 2010 May; 55(5):450-5. PubMed ID: 20509178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiac resynchronization therapy-always with ICD?].
    Stellbrink C
    Herz; 2005 Nov; 30(7):596-600. PubMed ID: 16333584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
    Pezawas T; Stix G; Kastner J; Schneider B; Wolzt M; Schmidinger H
    Int J Cardiol; 2006 Mar; 107(3):360-8. PubMed ID: 16503259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death.
    Klein MH; Gold MR
    Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary prevention of sudden cardiac death implanted cardioverter defibrillator (ICD) versus antiarrhythmic drugs].
    Iturralde Torres P
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-129-32. PubMed ID: 18938711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sudden cardiac death risk stratification and assessment: primary prevention based on ejection fraction criteria.
    Saba S
    Heart Fail Clin; 2011 Apr; 7(2):175-83, vii. PubMed ID: 21439496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Vyas AK; Hall WJ; Moss AJ; Wang H; He H; Zareba W; McNitt S; Andrews ML;
    J Am Coll Cardiol; 2008 Jan; 51(3):288-96. PubMed ID: 18206738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter-defibrillator therapy and the total burden of sudden cardiac death.
    Huikuri HV
    Europace; 2009 Dec; 11(12):1574. PubMed ID: 19933771
    [No Abstract]   [Full Text] [Related]  

  • 18. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.
    Sweeney MO; Hellkamp AS; Ellenbogen KA; Lamas GA
    J Cardiovasc Electrophysiol; 2008 Nov; 19(11):1160-6. PubMed ID: 18554201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
    Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.